NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market on Wednesday that its fourth-quarter revenues declined 6 percent and it swung from a profit in the 2007 fourth quarter to a loss.

The Omaha, Neb.-based pharmacogenomics assay developer and lab services firm had revenues of $6.1 million for the three-month period ended December 31, compared to revenues of $6.5 million for the fourth quarter of 2007.

It swung to a net loss of $219,000, or $.00, per share, from a profit of $212,000, or $.00 per share, in the fourth quarter of 2007.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.